

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

IN RE APPLICATION OF:	Colombo et al.	:	Confirmation No.: 2887
APPLICATION NO.:	10/714,166	:	Examiner: E. Peselev
FILING DATE:	November 14, 2003	:	Group Art Unit: 1623
TITLE:	DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS	:	

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)**

A shortened statutory response to the Office Action mailed on March 2, 2007 was initially set to expire three (3) months from the mailing date of the Office Action, i.e., June 2, 2007. Pursuant to the provisions of 37 C.F.R. §1.136(a), Applicants request that the time for responding to the Office Action mailed on March 2, 2007, be extended by one (1) month, such that it expires on July 2, 2007.

Authorization is hereby provided to charge the amount of \$120.00, as stated under 37 C.F.R. §1.17, as well as any additional fees required, or to credit any overpayment to Applicants' Deposit Account No. 16-1445.

Respectfully submitted,

Date: July 2, 2007

/David L. Kershner/  
David L. Kershner  
Attorney for Applicant  
Reg. No. 53,112

Pfizer Inc  
Patent Dept. -- 5<sup>th</sup> Floor  
150 East 42<sup>nd</sup> Street  
New York, NY 10017-5612  
(212) 733-0538